Literature DB >> 30607546

Efficacy and Safety of Deep Sedation in Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma.

Koki Sato1, Nobuhito Taniki2, Ryo Kanazawa2, Motonori Shimizu2, Shigeto Ishii2, Hideko Ohama2, Masashi Takawa2, Hiroaki Nagamatsu2, Yasuharu Imai2, Shuichiro Shiina2.   

Abstract

INTRODUCTION: Radiofrequency ablation (RFA) has been accepted as safe and effective for treating early-stage hepatocellular carcinoma (HCC). However, it often causes severe pain. Therefore, in this study, we performed RFA under deep sedation and investigated its efficacy and safety.
METHODS: We conducted a retrospective study including 511 HCC patients who received approximately 886 RFA treatments between December 2014 and November 2016 at our institution. Respiratory depression was defined as oxygen saturation of below 90%; and severe body movement was defined as movement caused by pain, which was managed by lowering the power of the generator. Factors associated with respiratory depression and severe body movement were examined via univariate and multivariate regression analyses.
RESULTS: Respiratory depression occurred in 15.3% of the patients and severe body movement in 26.5% of the patients. In the multivariate analysis, BMI (≥ 25 kg/m2, odds ratio [OR] = 1.75, P = 0.035) and longer ablation (≥ 10 min, OR = 2.59, P = 0.002) were significant respiratory depression-related factors. Male sex (OR = 2.02, P = 0.005), Child-Pugh class A (odds ratio = 1.96, P = 0.018), and longer ablation (≥ 10 min, OR = 3.03, P < 0.001) were significant factors related to severe body movement.
CONCLUSION: Deep sedation for RFA can be performed safely and effectively. Higher BMI and longer ablation were risk factors for respiratory depression and male sex, Child-Pugh class A, and longer ablation were independent predictors of severe body movement during RFA under deep sedation.

Entities:  

Keywords:  Deep sedation; Hepatocellular carcinoma; Percutaneous radiofrequency ablation; Respiratory depression; Severe body movement

Year:  2019        PMID: 30607546     DOI: 10.1007/s12325-018-0865-z

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  1 in total

1.  Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma.

Authors:  Naoya Kanogawa; Sadahisa Ogasawara; Yoshihiko Ooka; Masanori Inoue; Toru Wakamatsu; Masayuki Yokoyama; Susumu Maruta; Hidemi Unozawa; Terunao Iwanaga; Takafumi Sakuma; Naoto Fujita; Keisuke Koroki; Hiroaki Kanzaki; Takahiro Maeda; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Takayuki Kondo; Tomoko Saito; Tenyu Motoyama; Eiichiro Suzuki; Shingo Nakamoto; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Ryo Takemura; Natsuko Nozaki-Taguchi; Isono Shiroh; Osamu Yokosuka; Naoya Kato
Journal:  JGH Open       Date:  2020-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.